its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market. Lilly’s ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight ... The test drug combines semaglutide, ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way ...

such as aiming for greater weight loss than Wegovy or the same as Zepbound. Martin Holst Lange, Novo Nordisk’s executive vice president for development, said Novo was “encouraged” by the data.

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...

Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...